SCHEMBL6367458

SCHEMBL6367458

CCCCc1cc(F)ccc1/C=C/C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.46
ESR1 P03372 3/20 0.44
ESR2 Q92731 2/20 0.44
MIF P14174 1/20 0.44
AGTR1 P30556 2/20 0.42
AGTR2 P50052 2/20 0.42
PTGER4 P35408 2/20 0.42
PTGER3 P43115 2/20 0.42
PTGER2 P43116 2/20 0.42
KDM4E B2RXH2 3/20 0.42
HTT P42858 1/20 0.42
EGFR P00533 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
PPARA Q07869 1/20 0.38
EIF4A1 P60842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL957117 0.91 TDO2 (0.48) TDO2ESR1MIFPTGER4PTGER3
SCHEMBL957118 0.91 TDO2 (0.48) TDO2ESR1MIFPTGER4PTGER3
SCHEMBL7937601 0.84 MIF (0.53) ESR1ESR2MIFPTGER4PTGER3
SCHEMBL7937596 0.84 MIF (0.53) ESR1ESR2MIFPTGER4PTGER3
SCHEMBL28552435 0.84 ATG4B (0.48) PTGER4PTGER3PTGER2KDM4EEGFR
SCHEMBL955439 0.82 ESR1 (0.46) ESR1MIFKDM4EALDH1A1PPARA
SCHEMBL955440 0.82 ESR1 (0.46) ESR1MIFKDM4EALDH1A1PPARA
SCHEMBL1322604 0.82 ESR1 (0.43) ESR1ESR2PTGER4PTGER3PTGER2
SCHEMBL6367849 0.81 PTGER4 (0.49) ESR1ESR2PTGER4PTGER3PTGER2
SCHEMBL5178122 0.81 PTGER4 (0.49) ESR1ESR2PTGER4PTGER3PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050010068-A1 Use of microencapsulated transition metal reagents for reactions in supercritical fluids AVECIA LIMITED (GB) 2005-01-13 US disclosed
EP-1453780-A1 THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS Avecia Limited (GB) 2004-09-08 EP disclosed
WO-2003048090-A1 THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS AVECIA LIMITED (GB) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010068-A1 Use of microencapsulated transition metal reagents for reactions in supercritical fluids HPSE, SIK1, SGK1 TDO2 1491/4885ESR1 3170/4885ESR2 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.